CYCN - Cyclerion Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.17
+0.11 (+0.91%)
As of 12:01PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close12.06
Open12.02
Bid12.10 x 900
Ask12.17 x 800
Day's Range11.65 - 12.30
52 Week Range9.06 - 22.85
Volume15,523
Avg. Volume179,719
Market Cap333.479M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.65
Earnings DateJul 29, 2019 - Aug 2, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP

    Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that three upcoming data presentations will be made on two of its clinical-stage pipeline candidates during the 9th International Conference on cGMP, held June 14-16 in Mainz, Germany. One presentation will discuss the results of a series of preclinical studies on IW-6463, Cyclerion’s central nervous system (CNS)-penetrant sGC stimulator designed to address serious neurodegenerative diseases, showing an association between treatment with IW-6463 and decreased markers of neuroinflammation, enhanced blood flow in brain regions associated with cognition, improved dendritic spine density and structure and restored cognitive performance.

  • Ironwood Initiates Dosing in Mid-Stage Study for MD-7246
    Zacks2 months ago

    Ironwood Initiates Dosing in Mid-Stage Study for MD-7246

    Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.

  • GuruFocus.com2 months ago

    3 Spinoff Stocks Worth Your Attention

    Joel Greenblatt (Trades, Portfolio)'s "You Can Be a Stock Market Genius" prompted many investors to follow spinoff stocks with close attention. Gurus like Peter Lynch, Charlie Munger (Trades, Portfolio) and Seth Klarman (Trades, Portfolio) do as well. Warning! GuruFocus has detected 1 Warning Sign with BCS.

  • GlobeNewswire2 months ago

    Cyclerion Therapeutics to Present Data on its Sickle Cell Disease Program at Upcoming Medical and Scientific Meetings

    Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced upcoming data presentations supporting its therapeutic approach in sickle cell disease (SCD) during the 24th European Hematology Association (EHA) Congress, held June 13-16 in Amsterdam. The company will also present an overview of olinciguat, its sGC stimulator under clinical investigation in the Phase 2 STRONG SCD study as a potential treatment for sickle cell disease, at the 13th Annual Sickle Cell Disease Research and Educational Symposium, hosted by the Foundation for Sickle Cell Disease Research (FSCDR), and held June 7-9 in Fort Lauderdale, Florida.

  • GlobeNewswire2 months ago

    Cyclerion Therapeutics Provides a Corporate and Pipeline Overview as a Newly Launched Public Biopharmaceutical Company

    Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today provided a general corporate and pipeline overview, as well as financial results for the first quarter of 2019. “Cyclerion launched with the mission of developing life changing medicines for patients suffering from serious and orphan diseases through the modulation of soluble guanylate cyclase,” said Peter Hecht, Ph.D., chief executive officer of Cyclerion. “Our team is advancing a pipeline of differentiated and wholly owned sGC stimulator therapeutic candidates with compelling preclinical and clinical data.

  • GlobeNewswire3 months ago

    Cyclerion to Host Corporate Overview Call on May 13, 2019

    Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it will host a conference call and live audio webcast on Monday, May 13, 2019 at 8:30 a.m. Eastern Time. For its first webcast conference call as a public company, Cyclerion intends to provide a general corporate overview and discuss its clinical and preclinical development pipeline.

  • Cyclerion taps ex-Shire exec as chief innovation officer
    American City Business Journals3 months ago

    Cyclerion taps ex-Shire exec as chief innovation officer

    Cyclerion has hired the former chief medical officer at Shire plc for a new, overarching role focused on bridging R&D;, external partnerships and other business facets.

  • GlobeNewswire4 months ago

    Cyclerion Launches as Clinical-Stage Biopharmaceutical Company Harnessing the Power of Soluble Guanylate Cyclase (sGC) Pharmacology for Treatment of Serious and Orphan Diseases

    Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced its launch as an independent, publicly traded clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. “We are excited to unleash the terrific Cyclerion team and further our laser-focused mission to advance tailored sGC stimulators to patients with serious and orphan diseases,” said Peter Hecht, chief executive officer of Cyclerion.